|
시장보고서
상품코드
2055149
부정맥 시장 : 부정맥 유형별, 약제 클래스별, 투여 경로별, 약제 유형별, 연령층별, 최종 사용자별, 유통 채널별, 지역별Arrhythmia Market, By Arrhythmia Type, By Drug Class, By Route of Administration, By Drug Type, By Age Group, By End User, By Distribution Channel, By Geography |
||||||
부정맥 시장은 2026년에 181억 2,000만 달러에 달하고 2033년까지 260억 1,000만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR은 5.3%를 나타낼 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 181억 2,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 5.30% | 예측 금액(2033년) | 260억 1,000만 달러 |
세계 부정맥 시장은 심혈관 치료 및 의료기기 산업에서 중요한 분야로, 전 세계 수백만 명에게 영향을 미치는 가장 흔한 심장 질환 중 하나를 다루고 있습니다. 서맥, 빈맥, 심방세동 등을 특징으로 하는 부정맥은 고령화, 앉아 있는 시간이 많은 생활 습관, 그리고 심혈관 질환 유병률 증가를 배경으로 중요한 보건 의료 과제로 대두되고 있습니다. 이 시장은 항부정맥제, 이식형 제세동기(ICD), 심박조율기, 카테터 절제술 장치, 첨단 심장 모니터링 시스템 등의 종합적인 치료법을 대상으로 합니다.
3차원 매핑 시스템, 냉동 절제술, 소형화된 이식형 기기 등 전기생리학 분야의 기술 혁신은 치료 방식에 혁명을 일으켰으며, 환자의 예후를 크게 개선했습니다. 의료비 증가, 진단 능력 향상, 심장 건강에 대한 인식 제고, 그리고 혁신적인 치료법의 승인을 신속히 처리할 수 있도록 지원하는 규제 체계 덕분에 시장 성장세는 더욱 가속화되고 있습니다. 또한, 심장 리듬 관리에 인공지능(AI)과 머신러닝을 통합하고, 원격 환자 모니터링을 위한 원격 헬스케어 플랫폼을 도입함으로써 시장 확대를 위한 새로운 길이 열렸으며, 전 세계 다양한 지역과 의료 환경에서 부정맥 치료에 대한 접근성이 향상되고 그 효과도 높아지고 있습니다.
시장 역학
세계 부정맥 시장은 지속적인 성장과 혁신을 위한 견고한 기반을 마련하는 몇 가지 강력한 시장 성장 촉진요인에 힘입어 성장하고 있습니다. 주요 성장 요인은 전 세계 심혈관 질환 유병률 증가에 기인하며, 고령화가 진행되는 인구 구조가 부정맥 발생률 증가에 크게 기여하고 있습니다. 이는 고령자가 자연스러운 생리적 변화나 동반 질환으로 인해 심장 리듬 장애에 걸리기 쉽기 때문입니다. 기술의 발전 또한 중요한 촉진요인으로 작용하고 있으며, 여기에는 최소 침습 수술 분야의 획기적인 혁신, 배터리 수명 연장 및 무선 연결 기능을 갖춘 차세대 이식형 기기, 그리고 시술의 정밀도와 환자 안전성을 높이는 첨단 전기생리학적 매핑 시스템 등이 포함됩니다.
그러나 시장에는 뚜렷한 제약도 존재합니다. 특히, 첨단 심장 기기나 시술에 따른 고액의 치료비가 의료 예산이 제한적인 신흥국에서 의료 접근성을 저해하는 요인이 되고 있습니다. 의료기기에 대한 엄격한 규제 및 승인 절차는 추가적인 장벽이 되어 개발 기간을 연장시키고 막대한 투자를 필요로 하는 경우가 많아, 중소 제조업체 시장 진입을 저해할 가능성이 있습니다. 또한, 의료 제도마다 다른 복잡한 보험 급여 상황도 시장의 과제를 더욱 심각하게 만들고 있으며, 보험 적용 방침의 불일치로 인해 환자가 최적의 치료 옵션을 받지 못할 우려가 있습니다.
이러한 제약이 있음에도 불구하고, 개발도상국에서의 의료 인프라 확충, 건강 증진 프로그램의 확대, 그리고 환자의 장기적인 치료 성과를 중시하는 가치 기반 의료 모델의 보급으로 인해 큰 성장 기회가 창출되고 있습니다. 원격 모니터링 기능이나 AI 기반 진단 도구 등 디지털 헬스케어 기술의 통합은 맞춤형 치료 접근을 가능하게 하고, 환자의 치료 순응도를 높임으로써 큰 성장 기회를 가져다줍니다. 한편, 기술 기업과 의료 제공업체 간의 전략적 제휴는 시너지 효과를 창출하여 시장 침투와 혁신 도입을 가속화합니다.
본 보고서의 주요 특징
- 본 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 시장 성장 촉진요인과 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 관한 중요한 분석도 제공합니다.
- 세계 부정맥 시장의 주요 기업 프로파일을 다양한 지표(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등)를 바탕으로 소개합니다.
- 본 보고서의 인사이트를 바탕으로 마케팅 담당자와 기업 경영진은 향후 제품 출시, 제품 라인업 개편, 시장 확대 및 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
- “세계 부정맥 시장” 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자들을 대상으로 합니다.
- 이해관계자들은 세계의 부정맥 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 할 수 있습니다.
목차
제1장 분석 목적 및 전제 조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 부정맥 시장 : 부정맥 유형별(2021-2033년)
제5장 세계의 부정맥 시장 : 약제 클래스별(2021-2033년)
제6장 세계의 부정맥 시장 : 투여 경로별(2021-2033년)
제7장 세계의 부정맥 시장 : 약제 유형별(2021-2033년)
제8장 세계의 부정맥 시장 : 연령층별(2021-2033년)
제9장 세계의 부정맥 시장 : 최종 사용자별(2021-2033년)
제10장 세계의 부정맥 시장 : 유통 채널별(2021-2033년)
제11장 세계의 부정맥 시장 : 지역별(2021-2033년)
제12장 경쟁 구도
제13장 애널리스트의 제안
제14장 참고 문헌 및 분석 방법
KTH 26.06.19Arrhythmia Market is estimated to be valued at USD 18.12 Bn in 2026 and is expected to reach USD 26.01 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 18.12 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.30% | 2033 Value Projection: | USD 26.01 Bn |
The global arrhythmia market represents a critical segment within the cardiovascular therapeutics and medical device industry, addressing one of the most prevalent cardiac conditions affecting millions worldwide. Arrhythmia, characterized by irregular heartbeat patterns including bradycardia, tachycardia, and atrial fibrillation, has emerged as a significant healthcare challenge driven by aging populations, sedentary lifestyles, and increasing prevalence of cardiovascular diseases. The market encompasses a comprehensive range of treatment modalities including antiarrhythmic drugs, implantable cardioverter defibrillators (ICDs), pacemakers, catheter ablation devices, and advanced cardiac monitoring systems.
Technological innovations in electrophysiology, including three-dimensional mapping systems, cryoablation techniques, and miniaturized implantable devices, have revolutionized treatment approaches and improved patient outcomes significantly. The market's growth trajectory is further accelerated by rising healthcare expenditure, enhanced diagnostic capabilities, growing awareness about cardiac health, and supportive regulatory frameworks facilitating faster approval of innovative therapeutic solutions. Additionally, the integration of artificial intelligence and machine learning in cardiac rhythm management, coupled with telemedicine platforms for remote patient monitoring, has opened new avenues for market expansion, making arrhythmia treatment more accessible and effective across diverse geographical regions and healthcare settings globally.
Market Dynamics
The global arrhythmia market is propelled by several compelling drivers that create a robust foundation for sustained growth and innovation. The primary growth driver stems from the escalating prevalence of cardiovascular diseases worldwide, with aging demographics significantly contributing to increased arrhythmia incidence rates, as elderly populations are more susceptible to cardiac rhythm disorders due to natural physiological changes and comorbidities. Technological advancement serves as another crucial driver, with breakthrough innovations in minimally invasive procedures, next-generation implantable devices featuring extended battery life and wireless connectivity, and sophisticated electrophysiology mapping systems that enhance procedural precision and patient safety.
However, the market faces notable restraints including high treatment costs associated with advanced cardiac devices and procedures, which limit accessibility particularly in emerging economies with constrained healthcare budgets. Stringent regulatory approval processes for medical devices create additional barriers, often resulting in lengthy development timelines and substantial investment requirements that may deter smaller manufacturers from market entry. Complex reimbursement scenarios across different healthcare systems further compound market challenges, as inconsistent coverage policies can restrict patient access to optimal treatment options.
Despite these constraints, significant opportunities emerge through expanding healthcare infrastructure in developing nations, increasing healthcare awareness programs, and growing adoption of value-based care models that emphasize long-term patient outcomes. The integration of digital health technologies, including remote monitoring capabilities and AI-powered diagnostic tools, presents substantial growth opportunities by enabling personalized treatment approaches and improving patient compliance, while strategic partnerships between technology companies and healthcare providers create synergies that accelerate market penetration and innovation adoption.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global arrhythmia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc, Sanofi SA, GlaxoSmithKline plc, Novartis AG, Merck & Co Inc, Johnson & Johnson, AstraZeneca plc, Bayer AG, Roche Holding AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Mylan (Viatris), Eli Lilly and Company, Boehringer Ingelheim GmbH, and Lupin Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global arrhythmia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global arrhythmia market
Market Segmentation
- Arrhythmia Type Insights (Revenue, USD Bn, 2021 - 2033)
- Atrial Fibrillation
- Atrial Flutter
- Supraventricular Tachycardia
- Ventricular Tachycardia
- Ventricular Fibrillation
- Bradyarrhythmia
- Premature Contractions (PACs and PVCs)
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Anticoagulants and Antiplatelets (e.g., Warfarin, Apixaban, Aspirin)
- Class I Sodium Channel Blockers (e.g., Flecainide, Procainamide)
- Class II Beta Blockers (e.g., Metoprolol, Propranolol)
- Class III Potassium Channel Blockers (e.g., Amiodarone, Dofetilide)
- Class IV Calcium Channel Blockers (e.g., Verapamil, Diltiazem)
- Others (such as Digitalis Glycosides, etc.)
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
- Branded
- Generic
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Pediatric
- Adult
- Geriatric
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals and Cardiac Specialty Clinics
- Ambulatory Surgical Centers (ASCs)
- Diagnostic and Catheterization Labs
- Home Healthcare Settings
- Ambulatory Surgical Centers
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc
- Sanofi SA
- GlaxoSmithKline plc
- Novartis AG
- Merck & Co Inc
- Johnson & Johnson
- AstraZeneca plc
- Bayer AG
- Roche Holding AG
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd
- Mylan (Viatris)
- Eli Lilly and Company
- Boehringer Ingelheim GmbH
- Lupin Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Arrhythmia Market, By Arrhythmia Type
- Global Arrhythmia Market, By Drug Class
- Global Arrhythmia Market, By Route of Administration
- Global Arrhythmia Market, By Drug Type
- Global Arrhythmia Market, By Age Group
- Global Arrhythmia Market, By End User
- Global Arrhythmia Market, By Distribution Channel
- Global Arrhythmia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Arrhythmia Market, By Arrhythmia Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Atrial Fibrillation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Atrial Flutter
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Supraventricular Tachycardia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ventricular Tachycardia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ventricular Fibrillation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Bradyarrhythmia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Premature Contractions (PACs and PVCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Arrhythmia Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Anticoagulants and Antiplatelets (e.g., Warfarin, Apixaban, Aspirin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Class I Sodium Channel Blockers (e.g., Flecainide, Procainamide)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Class II Beta Blockers (e.g., Metoprolol, Propranolol)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Class III Potassium Channel Blockers (e.g., Amiodarone, Dofetilide)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Class IV Calcium Channel Blockers (e.g., Verapamil, Diltiazem)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (such as Digitalis Glycosides, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Arrhythmia Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Arrhythmia Market, By Drug Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Arrhythmia Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Arrhythmia Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals and Cardiac Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Diagnostic and Catheterization Labs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Home Healthcare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Arrhythmia Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Arrhythmia Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Arrhythmia Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Arrhythmia Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Arrhythmia Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Arrhythmia Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Arrhythmia Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Arrhythmia Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan (Viatris)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
